All In Biotech

Drug Trial Radar · NCT05572515

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 614 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

614

Actual

Start

Mar 29, 2023

Primary completion

Oct 13, 2025

Study completion Aug 31, 2031

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Oct 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.

Conditions

  • Multiple Myeloma

Interventions

  • TeclistamabDrug

    Teclistamab will be administered subcutaneously.

  • PomalidomideDrug

    Pomalidomide will be administered orally.

  • BortezomibDrug

    Bortezomib will be administered subcutaneously.

  • DexamethasoneDrug

    Dexamethasone will be administered orally in PVd and intravenously or orally in Kd.

  • CarfilzomibDrug

    Carfilzomib will be administered intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Progression-free Survival (PFS)Time frame: Up to 9 years
  2. Part 2: Number of Participants Reporting Cytokine Release Syndrome (CRS) Cases by SeverityTime frame: Up to 9 years

Locations

211 sites in 24 countries. Site status is shown where the registry gives one.

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Alta Bates Comprehensive Cancer Center

    Berkeley, California

  • MemorialCare Long Beach Medical Center

    Long Beach, California

  • University of California Irvine

    Orange, California

  • PIH Health Hospital

    Whittier, California

  • Rocky Mountain Cancer Centers

    Aurora, Colorado

  • University of Connecticut

    Farmington, Connecticut

  • University of Miami Sylvester Cancer Center

    Miami, Florida

  • Orlando Health Cancer Institute

    Orlando, Florida

  • Cleveland Clinic Florida

    Weston, Florida

  • Mission Cancer Blood

    Waukee, Iowa

  • East Jefferson General Hospital Bone Marrow Transport Clinic

    Metairie, Louisiana

  • Walter Reed National Military Medical Center

    Bethesda, Maryland

  • Maryland Oncology Hematology P A

    Silver Spring, Maryland

  • Boston University Medical Center

    Boston, Massachusetts

  • Saint Lukes Hospital Saint Lukes Cancer Specialists

    Chesterfield, Missouri

  • Cooper Health System MD Anderson Cancer Center at Cooper

    Camden, New Jersey

  • Herbert Irving Comprehensive Cancer Center Columbia University Medical Center

    New York, New York

  • Durham VAMC

    Durham, North Carolina

  • Penn Medicine Lancaster General Health

    Lancaster, Pennsylvania

  • Tennessee Oncology

    Nashville, Tennessee

  • Brooke Army Medical Center

    Fort Sam Houston, Texas

  • Baylor College of Medicine

    Houston, Texas

  • Michael E DeBakey VA Medical Center

    Houston, Texas

  • Harris Health Smith Clinic

    Houston, Texas

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • Alexander T. Augusta Military Medical Center

    Fort Belvoir, Virginia

  • Virginia Oncology Associates

    Norfolk, Virginia

  • NorthWest Medical Specialties, PLLC

    Tacoma, Washington

  • Blacktown Hospital

    Blacktown, Australia

  • St Vincents Hospital Melbourne

    Fitzroy, Australia

  • Box Hill Hospital

    Melbourne, Australia

  • Fiona Stanley Hospital

    Murdoch, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Australia

  • LKH - Universitätsklinikum der PMU Salzburg

    Salzburg, Austria

  • Medical University Vienna MUV

    Vienna, Austria

  • Algemeen Ziekenhuis Klina

    Brasschaat, Belgium

  • Jolimont

    Haine-St-Paul, Belgium

  • Az Groeninge

    Kortrijk, Belgium

Showing 40 of 211 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.